Bladder cancer is one of the most common urological cancers, and early diagnosis can improve treatment outcomes. This article covers the symptoms, causes, diagnosis, staging and standard treatment options available in Germany, including TURBT, BCG therapy, surgery, chemotherapy and immunotherapy. It also explains selected advanced therapies, such as targeted embolization and dendritic cell therapy, along with survival rates, treatment costs and support for international patients.

Bladder Cancer in Germany: Symptoms, Diagnosis & Treatment

Bladder cancer is one of the most common cancers, and one of the most treatable when it is caught early. More than 30,000 new cases are diagnosed each year, around 18,000 once carcinoma in situ is excluded, which makes it the fifth most common cancer in the country [6]. Most patients first notice blood in the urine, which is often the earliest sign of bladder cancer. International patients who choose treatment in Germany often need support with medical record review, hospital coordination, travel planning and follow-up care. TIG GmbH provides these services throughout the treatment journey.

What Is Bladder Cancer and How Does It Develop?

Bladder cancer develops when cells in the bladder lining grow uncontrollably after years of damage from carcinogens, most commonly those found in tobacco smoke. Most bladder cancers begin in the urothelium, the inner lining of the bladder. These alterations are most commonly associated with long-term exposure to carcinogens, particularly those found in tobacco smoke, although occupational exposures, chronic inflammation and other factors also contribute [1].

Doctors describe it as a field disease, because the entire lining is exposed to the same chemicals at the same time. This is why tumours often appear at several sites at once, and why bladder cancer returns so frequently even after a tumour has been completely removed. 

Types of Bladder Cancer

Urothelial carcinoma accounts for about 90% of all cases. The other types are far less common, and each has a slightly different cause and behaviour [1] [6] [2]. 

Non-Muscle-Invasive vs Muscle-Invasive Disease

This distinction is central to bladder cancer management because almost every treatment decision depends on how deeply the tumour has grown into the bladder wall. Non-muscle-invasive bladder cancer stays in the lining or the layer just beneath it, and about 75% of patients have this type when they are first diagnosed [1]. In most of these patients the bladder can be saved. Muscle-invasive bladder cancer has grown into the bladder muscle itself, which calls for more intensive treatment and often means the bladder needs to be removed.

What Causes Bladder Cancer and Who Is at Risk?

Bladder cancer is caused mainly by long-term exposure to tobacco smoke and certain workplace chemicals. Older adults, smokers and people exposed to industrial carcinogens have the highest risk of developing the disease. 

Common Causes and Risk Factors for Bladder Cancer

Smoking is the single biggest cause by a wide margin. One review links 50% to 65% of all cases to tobacco smoke, and around 20% to occupational or environmental toxins [2]. The risk does not disappear when someone quits, because current smokers carry 3.5 times the risk of never-smokers, and former smokers still carry 2.0 times the risk [3].

• Workplace chemicals: aromatic amines, polycyclic aromatic hydrocarbons and chlorinated hydrocarbons, historically used in dye, rubber, paint and chemical work [3].
• Contaminated water: long-term consumption of arsenic-contaminated or heavily chlorinated drinking water [3].
• Chronic infection: long-standing bladder inflammation and schistosomiasis, which is a major cause in regions where the parasite is common [2].
• Diet: a diet high in red and processed meat, which shows a consistent though modest link [1].

Who Is Most Likely to Develop Bladder Cancer?

Age is the most important factor you cannot change. The median age at diagnosis is close to 70 [1], and around 90% of cases occur in people aged 55 or over, with an average age of 73 [2]. Men are affected far more often than women, and this gap remains even after accounting for differences in smoking and workplace exposure. Women, however, are usually diagnosed later and with more advanced disease, because their bleeding is often attributed to gynaecological causes before bladder cancer is considered [1].

What Are the Signs and Symptoms of Bladder Cancer?

The most common symptom of bladder cancer is painless blood in the urine, which may come and go. Early bladder cancer often causes few symptoms, so many patients feel well and mistake the early warning signs for a minor urinary problem.

Early Signs of Bladder Cancer

Blood in the urine may be clearly visible, or it may only show up when a urine sample is tested. Either way it is the symptom that matters most, and it appears the same way in men and women, though bleeding in women is more often first attributed to gynaecological causes or infection [1].

• Visible blood: pink, red or cola-coloured urine, usually with no pain at all.
• Microscopic haematuria: blood detected on urine dipstick testing and confirmed by microscopic examination, without visible discoloration of the urine.
• Frequency or urgency: needing to pass urine more often than usual, when no infection can be found.
• Burning on passing urine: together with urine tests that keep coming back clear.
• Repeated urine infections: that keep returning after each course of antibiotics.

More advanced disease produces different symptoms, because the cancer has spread beyond the bladder. These can include flank pain, swelling in the legs, bone pain and unexplained weight loss.

When Should You See a Doctor?

You should see a doctor after a single episode of visible blood in the urine, even if it clears completely and never comes back. Waiting to see whetherthe bleeding recurs can postpone diagnosis and treatment, and it can cost valuable time which could potentially cause the disease to grow. It is also worth being checked for urinary symptoms that last more than a few weeks despite treatment, or for repeated infections in someone who has never had them before.

How Is Bladder Cancer Diagnosed?

Bladder cancer is diagnosed using cystoscopy, urine tests, imaging and tissue biopsy. Cystoscopy remains the most reliable test because it allows doctors to examine the bladder lining directly and obtain tissue for confirmation.

Which Tests Are Used to Diagnose Bladder Cancer?

In one study of 565 cystoscopies, the test correctly identified cancer 81% of the time and correctly ruled it out 73% of the time. Among 181 patients whose examination looked normal, 17 (9.4%) were later found to have bladder cancer [4]. For this reason, cystoscopy is combined with other diagnostic tests rather than being used on its own.

How Is Bladder Cancer Staged?

Staging uses the TNM system, which records how deep the tumour has grown, whether it has reached the lymph nodes, and whether it has spread to distant organs [1]. The stages below explain how far the cancer has spread and how they guide treatment decisions.

What Are the Treatment Options for Bladder Cancer in Germany?

Treatment for bladder cancer in Germany depends on the stage of the disease. Options include TURBT, BCG therapy, radical cystectomy, chemotherapy, immunotherapy and selected advanced treatments for carefully chosen patients.

Standard Bladder Cancer Treatments

TURBT is the first step for almost every patient, and it removes the tumour through the urethra so that no cut is made in the skin. The tissue that is removed provides histopathological confirmation of the diagnosis and determines tumour grade and the depth of invasion (pathological stage), which, together with imaging findings and guides further treatment. A single dose of chemotherapy is then placed into the bladder, ideally within two to six hours and no later than 24 hours, because this lowers the chance of the cancer returning.

BCG therapy follows for intermediate-risk and high-risk patients, and it uses a live vaccine placed directly into the bladder to trigger an immune reaction against the tumour. The course begins with six weekly treatments, followend by shorter maintenance courses that continue for 36 months in high-risk patients and 12 months in intermediate-risk patients [1].

Radical cystectomy removes the bladder and is the standard operation for muscle-invasive disease. Around three in four German patients with stage T2 or above have this surgery, and the number performed each year rose 28%, from 5,627 in 2006 to 7,292 in 2019 [5].

How Is Bladder Cancer Treatment Individualised in Germany? 

Treatment planning depends on the stage of the cancer, tumour characteristics, kidney function, overall health and previous treatments. Doctors also consider whether the disease is non-muscle-invasive, muscle-invasive or metastatic before recommending surgery, drug therapy or other treatment options. Lifelong follow-up with regular cystoscopy remains an important part of care because bladder cancer has a high risk of recurrence.

The table below summarizes the typical eligibility criteria for different bladder cancer treatments.

Treatment eligibility also depends on individual clinical factors. German data identify the most common reasons why some patients cannot receive platinum chemotherapy for advanced disease [6]. 

• Reduced kidney function: the recorded reason in 20.0% of patients.
• Other serious illness: the recorded reason in 15.6% of patients.
• Advanced age with reduced fitness: the recorded reason in 11.1% of patients.
• BCG-unresponsive disease: affects up to 21% of treated patients, who have worse survival than those who respond [1].

Targeted Embolization for Bladder Cancer Treatment in Germany

Targeted embolization is a minimally invasive catheter-based procedure that blocks the blood flow to a bladder tumour. It is used in selected situations and is considered an adjunct to standard bladder cancer treatment rather than a replacement.

How Targeted Embolization Works

During the procedure, a radiologist inserts a catheter through an artery in the groin and guides it to the blood vessels supplying the tumour. Tiny particles, microspheres or coils are then released to reduce the tumour's blood supply. In chemoembolisation procedures, these particles are combined with a chemotherapy drug to deliver treatment directly to the tumour.

As the tumour loses its blood supply, bleeding decreases significantly during later surgery. Treated tumours appear pale at cystoscopy, whereas untreated tumours remain red although evidence remains limited [8].

Who May Benefit from Targeted Embolization?

In one study, 11 patients with tumours of at least 5 cm had embolisation before their TURBT. The tumour was completely removed in every case, the average operating time was 78.8 minutes, and there were no complications. Six patients (54.5%) had a recurrence, but none progressed over a median follow-up of 24 months [8]. This is a small, single-arm study, and no randomised trial supports embolisation as a main treatment for bladder cancer, so it should not be offered as one.

Dendritic Cell Therapy for Bladder Cancer Treatment in Germany

Dendritic cell therapy is an investigational personalized immunotherapy that aims to stimulate the immune system to recognize cancer cells. Research is ongoing, and it is considered alongside, rather than instead of, standard treatment.

How Dendritic Cell Therapy Works

Monocytes are collected from the blood, matured into dendritic cells in a laboratory, loaded with a tumour antigen, and then injected back into the skin over several months [9]. The aim is to train the immune system to recognise and attack the cancer.

Who May Benefit from Dendritic Cell Therapy?

One phase I trial included 33 patients with HER2-positive cancers, of whom five had bladder cancer, and immune responses were newly triggered in 10 of 11 patients tested. Across the whole trial, 7 of 21 patients assessed (33.3%) had clinical benefit, made up of one complete response, one partial response and five with stable disease.

Two of the three bladder cancer patients treated after surgery stayed cancer-free for more than three years, though the trial authors state clearly that this result carries no statistical value. Safety was good, with injection-site reactions as the main side effect and no heart toxicity [9].

What Is the Prognosis and Survival Rate for Bladder Cancer?

The prognosis for bladder cancer depends mainly on the stage at diagnosis and how early treatment begins. Early-stage disease is often curable and earlier diagnosis is generally associated with better outcomes, while survival decreases once the cancer spreads beyond the bladder.

Can Bladder Cancer Be Cured?

Bladder cancer can often be cured when it is found before it reaches the muscle although recurrence remains common and lifelong surveillance is usually required. After a full course of BCG, five-year progression-free survival reached 100% in intermediate-risk patients and 91% in high-risk patients, with overall survival of 79% and 87% Long-term outcomes vary according to tumour risk, treatment response, and patient characteristics [1]. Survival becomes less favourable once the cancer invades the bladder muscle, although surgery can still provide long-term disease control for many patients.

What Are the Survival Rates by Stage?

The table below summarises reported five-year, ten-year and stage-specific survival rates. The metastatic survival figures differ because they were reported by different registries and during different study periods [2] [7].

How Does Metastatic Bladder Cancer Affect Prognosis?

German real-world data give a realistic picture of advanced disease. Among 188 patients treated first-line between 2019 and 2021, median overall survival was 18.0 months, median progression-free survival was 10.1 months, and tumours shrank in 58.1% of patients [6]. Newer drugs have improved these numbers considerably. In the EV-302 trial of 886 patients, enfortumab vedotin plus pembrolizumab gave a median overall survival of 31.5 months, compared with 16.1 months for chemotherapy alone [7].

What Are the Risks and Side Effects of Bladder Cancer and Its Treatment?

Bladder cancer and its treatments can cause different complications and side effects depending on the stage of the disease and the type of therapy used. Most side effects can be managed effectively with appropriate medical care.

What Complications Can Bladder Cancer Cause?

• Heavy bleeding: sometimes severe enough to need a transfusion or artery embolisation [8].
• Bladder perforation during surgery: most common with large tumours and linked to shorter disease-free survival [8].
• Progression to muscle invasion: the event most strongly associated with reduced quality of life [1].
• Understaging: which happens when the surgical sample contains no muscle [1].

What Are the Common Side Effects of Bladder Cancer Treatments?

What Does Medical Research Say About Advanced Bladder Cancer Treatments?

Current medical research strongly supports standard bladder cancer treatments, while evidence for targeted embolization and dendritic cell therapy remains limited to small clinical studies and early-phase research.

Clinical Evidence for Advanced Therapies

Standard drug treatment rests on large randomised trials, and EV-302 alone randomised 886 previously untreated patients [7]. 

What Is the Regulatory Status of Advanced Bladder Cancer Treatments in Germany?

Enfortumab vedotin with pembrolizumab is approved in Europe and recommended as the preferred first-line therapy for advanced disease [6]. By contrast, pembrolizumab and nadofaragene firadenovec were approved in the United States for BCG-unresponsive high-risk disease but had not received European approval for that use as of the 2023 review cited here [1].

Embolisation and dendritic cell therapy hold no marketing authorisation as bladder cancer treatments, which is precisely why both are delivered as individual treatment decisions rather than routine care and are generally offered only in carefully selected clinical circumstances, within research protocols, or as individualized treatment decisions after multidisciplinary evaluation. It is always worth asking a provider which category a proposed treatment falls into.

Why Choose Germany for Bladder Cancer Treatment?

Germany is recognized for guideline-based bladder cancer care, experienced multidisciplinary teams and access to advanced treatment options. Three in four patients with stage T2 or above receive radical cystectomy, and care is slowly centralising toward higher-volume units. Departments performing more than 50 cystectomies a year rose from 8 of 299 (2.7%) in 2006 to 17 of 360 (4.7%) in 2019, although 236 departments (66%) still performed fewer than 25 [5]. Higher surgical volumes have been associated with better outcomes, so patients should ask how many radical cystectomies a centre performs each year.

Leading Bladder Cancer Centers and Specialists in Germany

Entries 1 to 5 are confirmed from the author affiliations in the cited studies [5] [6], and entry 6 is based on provider information. Annual surgical volumes and robotic capability could not be verified from published sources, so confirm these directly with each centre before deciding.

How Much Does Bladder Cancer Treatment Cost in Germany?

The cost of bladder cancer treatment in Germany depends on the stage of the disease, the recommended treatment plan and the treating hospital. Individual cost estimates are prepared after a specialist reviews the patient's medical records and treatment requirements.

What Is Included in the Treatment Cost?

In Germany, dendritic cell therapy is provided by Prof. Gansauge at LDG Laboratories, who specialises in personalised dendritic cell immunotherapy and cellular cancer treatments. The complete treatment course costs approximately EUR 27,000.

Image-guided regional therapies such as TACE, TACP and TPCE are performed by Prof. Vogl at University Hospital Frankfurt. Depending on the procedure, treatment typically costs EUR 8,000 to EUR 9,000 per session. 

Which Factors Affect the Overall Treatment Cost?

• Stage at diagnosis, since recurrence and progression are the biggest cost drivers [1].
• Whether the bladder is removed and a urinary diversion is created [1].
• Number of drug cycles, given that German patients received a median of 4.0 platinum cycles and 13.0 immunotherapy cycles [6].
• Number of embolisation sessions needed, which depends on how the tumour responds.
• Length of stay, and whether a second resection is scheduled four to six weeks later [1].

How Can International Patients Access Bladder Cancer Treatment in Germany?

International patients can access bladder cancer treatment in Germany by submitting their medical records before travelling. Once the treatment plan is confirmed, appointments, travel arrangements and follow-up care are coordinated. TIG GmbH supports patients throughout this process by coordinating communication with German hospitals and helping organize treatment, travel and follow-up care.

• Medical report review: Pathology, imaging and operative notes are reviewed by a German specialist before travel is booked. 
• Second opinion: A written report from a urologist at a German centre, stating whether the proposed plan follows the guidelines. 
• Medical visa assistance: Invitation letters and supporting documents prepared for the visa application. 
• Interpreter support: Medical interpreters for consultations, consent discussions and discharge instructions. 
• Treatment coordination: Appointments, admission dates and the follow-up schedule arranged in the right order.

Send your pathology report, recent imaging and operative notes for review by a German urologist through TIG GmbH. A specialist review can help confirm the diagnosis, evaluate treatment options and support informed decision-making before travelling for care.

References

1. Grabe-Heyne, K., Henne, C., Mariappan, P., Geiges, G., Pöhlmann, J., & Pollock, R. F. (2023). Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Frontiers in oncology, 13, 1170124. 

2. Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P., Padala, S. A., & Barsouk, A. (2020). Epidemiology of Bladder Cancer. Medical sciences (Basel, Switzerland), 8(1), 15. 

3. Zhang, Y., Rumgay, H., Li, M., Yu, H., Pan, H., & Ni, J. (2023). The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. Journal of global health, 13, 04109. 

4. Guldhammer, C. S., Vásquez, J. L., Kristensen, V. M., Norus, T., Nadler, N., Jensen, J. B., & Azawi, N. (2023). Cystoscopy Accuracy in Detecting Bladder Tumors: A Prospective Video-Confirmed Study. Cancers, 16(1), 160. 

5. Flegar, L., Kraywinkel, K., Zacharis, A., Aksoy, C., Koch, R., Eisenmenger, N., Groeben, C., & Huber, J. (2022). Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019. World journal of urology, 40(7), 1715–1721. 

6. Schlack, K., Machtens, S., Kubin, T., Ruhnke, M., Schulte, C., Eisen, A., Osowski, U., Guenther, S., Kearney, M., Lipp, R., & Schmitz, S. (2025). Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study. Journal of cancer research and clinical oncology, 151(3), 100. 

7. Karam, E. A., Céline, Y. C., Prince, G., Attieh, F., Kourie, H. R., Kattan, J., & Nemer, E. (2025). Optimizing enfortumab vedotin plus pembrolizumab therapy. Oncotarget, 16, 481–494. 

8. Bang, S., Joo, S. M., Kim, D. K., Kwon, J. K., Bang, S., Shin, D., Jeon, J., Hong, S. H., & Cho, K. S. (2026). Preoperative selective arterial embolization followed by transurethral resection of bladder tumor for large bladder tumors: Early clinical experiences. Investigative and clinical urology, 67(2), 162–169. 

9. Maeng, H. M., Moore, B. N., Bagheri, H., Steinberg, S. M., Inglefield, J., Dunham, K., Wei, W. Z., Morris, J. C., Terabe, M., England, L. C., Roberson, B., Rosing, D., Sachdev, V., Pack, S. D., Miettinen, M. M., Barr, F. G., Weiner, L. M., Panch, S., Stroncek, D. F., Wood, L. V., … Berzofsky, J. A. (2021). Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy. Frontiers in oncology, 11, 789078. 

10. Heard, J. R., & Mitra, A. P. (2024). Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays. Bladder cancer (Amsterdam, Netherlands), 10(1), 71–81.

Why Patients Worldwide Prefer Our Medical Services in Germany – Key Benefits Explained